“ New Evidence Indicates ATH434 can Function as an Iron Chaperone to Redistribute Iron “ MELBOURNE, Australia and SAN FRANCISCO, April 29, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX:...
“ ATH434 Improved Motor Performance and General Function in a Primate Model of Parkinson's Disease “ “ ATH434-201 Phase 2 Baseline Data Confirm Approach to Target Biomarkers for Slowing...
MELBOURNE, Australia and SAN FRANCISCO, April 10, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (€œAlterity€ or €œthe Company€), a biotechnology company dedicated to...
Alterity Therapeutics Receives a A$3.9M R&D Tax Incentive Refund
Positive Efficacy Data for ATH434 in a Primate Model of Parkinson™s Disease to be Presented at International Conference Baseline Biomarker Data to be Presented from Ongoing ATH434-201 Phase 2...
- ATH434-201 Trial on Track to Complete in November 2024 “ - Top-Line Data Expected in January 2025 - MELBOURNE, AUSTRALIA AND SAN FRANCISCO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Alterity...
Alterity Therapeutics to Participate in ShareCafe Hidden Gems Webinar This Week
Preliminary Data from ATH434-202 Study Expected in 1H 2024 ATH434-201 Study to Complete in November 2024 MELBOURNE, Australia and SAN FRANCISCO, Jan. 22, 2024 (GLOBE NEWSWIRE) --...
MELBOURNE, Australia and SAN FRANCISCO, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (Alterity or the Company), a biotechnology company dedicated to...
- ATH434 improved motor performance and general function - Webcast to be held this week to discuss new data and recent clinical progress MELBOURNE, Australia and SAN FRANCISCO, Dec. 04,...